Tag: Motley Fool

A2 Milk Company Ltd (ASX: A2M) shares have been on a volatile journey over the last year. The share price is up 36% in 2024, but down 10% over the past 12 months.

A fund manager has picked out the dairy stock as an opportunity because of a potential catalyst that could send A2 Milk shares higher.

No one can say for sure when a share price is going to go up, but certain events can excite investors. Let’s look at why we should pay attention to this business that sells milk products that only contain the A2 protein type.

Exciting catalyst for A2 Milk shares

The investment team from Wilson Asset Management (WAM) have picked A2 Milk for the WAM Active Limited (ASX: WAA) portfolio.

Here’s one of the main reasons why they like the stock:

We believe that the launch of its new products in the second half of FY24, which include a2 Gentle Gold, two new English label infant formula products, and fortified milk powder products, positions the company to continue to deliver revenue growth.

WAM pointed out that A2 Milk recently reported an FY24 half-year result which beat market expectations.

The A2 Milk HY24 earnings before interest, tax, depreciation and amortisation (EBITDA) grew by 5%, with an increased market share in the Chinese infant milk formula market.

A2 Milk managed to achieve that despite a double-digit decline in the Chinese birth rate.

The WAM investment team said they were pleased to see A2 Milk decided to increase its FY24 revenue growth guidance from low to low-to-mid single-digit percent compared to the prior year.

Single-digit revenue growth may not sound exciting, but a share price usually includes a number of underlying assumptions. If the revenue achieved is better than expected, then it can be a catalyst to send the A2 Milk share price higher.

Valuation

Based on the current A2 Milk share price and using profit projections on Commsec, it’s valued at 26 times FY24 estimated earnings and 19 times FY26’s estimated earnings.

Time will tell if WAM is right to be excited about the dairy company, or whether things are going to go sour and other ASX shares would be better picks.

The post This new catalyst could make A2 Milk shares a buy appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/PxVGUlO

If you’re a growth investor and looking for new portfolio additions this week, then it could be worth checking out the three shares named below.

That’s because they have recently been tipped as buys by analysts.

Here’s why they are feeling bullish about these ASX 200 growth shares:

Life360 Inc (ASX: 360)

Goldman Sachs is a fan of this location technology company and sees it as a top option for investors even after rising strongly this year. It said:

360’s re-rate is only beginning, in our view, as it delivers solid subscription and EBITDA growth from the core business while opening up significant upside optionality via advertising monetisation.

FY24E EBITDA guidance appears conservative relative to the operating leverage demonstrated in FY23A and provides visibility to >50% growth in both FY24/25E.

Goldman currently has a buy rating and $14.20 price target on the ASX 200 growth share.

Lovisa Holdings Ltd (ASX: LOV)

Another ASX 200 growth share that analysts are positive on is fast fashion jewellery retailer Lovisa.

Morgans was very pleased with the company’s performance during the first half, noting that its result came in ahead of expectations. The good news is that it believes there’s more to come thanks to its global expansion. It said:

The 1H24 result surpassed expectations, mainly due to strong gross margins, which were supported by favourable changes to the price architecture. We have increased our EBIT estimate for the current year by 4%, but, for us, it’s not about the near-term. The investor should focus on what this business could develop into in the years ahead. We reiterate our Add rating and increase our target price.

Morgans has an add rating and $35.00 price target on its shares.

TechnologyOne Ltd (ASX: TNE)

Finally, this enterprise software provider could also be a top ASX 200 growth share to buy according to Goldman Sachs.

The broker is expecting TechnologyOne to achieve its annual recurring revenue (ARR) target and deliver mid to high teen earnings per share growth through to at least FY 2026. It explains:

In our view, the company is well placed to meet its A$500mn FY26 ARR target through a combination of SaaS flip uplift, net expansion and new customer growth. We see margin expansion resuming from FY24E onwards, which in combination with robust revenue growth should drive a mid-high teens EPS CAGR to FY26E, providing strong earnings visibility. TNE’s share price has historically been driven by its strong rate of compound earnings growth underpinned by its leading market position, high R&D investment and defensive public sector end markets.

Goldman has a buy rating and $18.05 price target on its shares.

The post Why these ASX 200 growth shares could be top buys now appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Why Bannerman Energy, Cettire, TechnologyOne, and Zip shares are charging higher
• 2 ASX growth stocks I’d buy for rapidly rising profit
• Guess which ASX 200 tech stock has just been upgraded
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has positions in Life360 and Lovisa. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Life360, Lovisa, and Technology One. The Motley Fool Australia has recommended Lovisa and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/9r8uKNq

The best-performing stock on the S&P/ASX 300 Index (ASX: XKO) over 2024 to date might surprise you. By the headline, you probably already know the answer, but just for the record, it is none other than buy now, pay later (BNPL) share Zip Co Ltd (ASX: ZIP).

This might come as a surprise to some investors because it wasn’t too long ago that Zip shares were something of a pariah on the ASX. Remember, this is a company that fell from over $14.50 a share in early 2021 to just 26 cents a share by October last year. That’s a wealth-destroying drop of 98.2%.

Yet investors who have bravely held on during this rollercoaster ride (or been better, bought in October) have enjoyed something of a reprieve in recent months.

Between 6 October and 31 December, Zip shares hopped on a rocket ship, gaining a whopping 146%. Since the beginning of 2024, we’ve seen another 120.97% added to the Zip share price.

That stonking gain is enough to crown Zip the best-performing ASX 300 share of the year so far.

What’s gone so right for Zip shares in 2024?

Well, Zip’s most recent success seems to be a result of two events in particular.

Firstly, Zip delivered a fairly impressive quarterly update back in January. The BNPL stock told investors that its transaction volumes rose 8.5% over the second quarter of FY2024. Revenues also rose by an even more luminous 26.1% to $225.6 million for the quarter.

Zip backed this up with its half-year earnings results in February too. The company reported a 28.9% rise in revenues for the six months to 31 December, as well as a cash gross profit of $176.2 million, which was up 45.9%.

Secondly, Zip’s January quarterly update prompted some rumours over February that Zip might be becoming an appealing target for a takeover. As we covered at the time, “‘multiple sources’ have suggested at least one possible suitor is eyeing up Zip, and it is ‘gaining interest’”.

We haven’t heard any more developments on that front, but this did give Zip shares a meaningful boost, and we are still seeing the momentum from this in the company’s stock price today.

So a wonderful start to 2024 for Zip shares. Let’s see what this BNPL share does over the rest of 2024.

The post Why is the Zip share price the best-performing ASX 300 stock so far this year? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why Bannerman Energy, Cettire, TechnologyOne, and Zip shares are charging higher
• If I’d put $5,000 into Zip shares on 9 October, here’s what I’d have now!
• Up 288% in 6 months, Zip share price tipped for more outsized gains
• Why Accent, Liontown, PSC Insurance, and Zip shares are charging higher today
• 4 ASX All Ords shares going gangbusters on Tuesday

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Zip Co. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/xPoCaIJ

There is no sweeter action in stock investing than picking up S&P/ASX 200 Index (ASX: XJO) stocks for cheap then watching it grow while everyone else catches up.

So in that spirit, there are two shares that Baker Young analyst Toby Grimm reckons are ripe to buy at a discount right now:

Take a long-term view of this ASX 200 beauty

The AGL Energy Limited (ASX: AGL) share price has tumbled more than 29% since last August’s reporting season.

The company has had many governance issues and boardroom fights over the past couple of years, but those problems seem to have largely settled down now.

The latest numbers were pretty good, Grimm told The Bull.

“The energy giant’s share price has continued to languish despite releasing better-than-expected first half earnings in fiscal year 2024 amid upgrading full year guidance.”

The trouble is that, after years of elevated prices, investors have been pricing in a weaker wholesale electricity market in 2025.

“Taking a longer term view, we believe the stock is materially undervalued,” said Grimm.

“Stronger earnings provide a solid foundation to fund renewable energy investments.”

AGL currently enjoys decent support from the professional community.

Broking platform CMC Invest shows eight out of 11 analysts recommending the stock as a buy.

Dividend producer that could rocket later this year

Packaging giant Amcor CDI (ASX: AMC) has struggled to launch upward momentum in its shares for a while now.

The stock is down more than 21% since December 2022.

Amcor has, however, handed out consistent dividends at a 5.3% yield, soothing the experience for its shareholders.

Grimm admitted last month’s reporting season did not flatter the global business headquartered in Zurich.

“The global packaging giant reported a soft set of results for the six months ending December 31, 2023, as customers in key markets delayed inventory restocking amid tougher retail conditions.”

There is a light at the end of the tunnel though.

“We see potential for a recovery later this year, as the company cuts costs and customer re-stocking improves,” said Grimm.

“We view the stock as attractive value at current levels.”

The post 2 ‘materially undervalued’ ASX 200 shares to buy while they’re at ‘attractive value’ appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• If history repeats itself, March could be one of the BEST times to buy cheap ASX shares
• Top ASX passive income shares to buy in March 2024
• Key takeouts for ASX shares this earnings season: CBA analysis
• Forget AGL: Buy this magnificent ASX utilities stock instead
• Passive income watch: The ASX stocks dishing out the biggest dividend boosts this earnings season

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Amcor Plc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/UGtnmD8

Resmed CDI (ASX: RMD) has been a staple in many ASX stock portfolios for decades now.

And it has rewarded the faith handsomely, becoming a 6-bagger over the past ten years. 

It’s a stunning 19-bagger if you go back 20 years.

Of course, the catch is that those investors who bought in March 2004 or 2014 would not have known with 100% certainty that their investment would become so successful.

That’s the nature of investing in shares. You buy them when they’re cheaper to take on the risk that the story could turn sour — or become a wild triumph.

There is one ASX stock at the moment that I think has the potential to become the next ResMed.

While I can’t tell you whether it will have become a 6-bagger in 2034, it currently has a fighting chance to be much higher compared to now.

This ASX stock has tripled in a year

Like ResMed, Clarity Pharmaceuticals Ltd (ASX: CU6) also plays in the healthcare field but is involved in developing products for prostate cancer.

Already this year the stock price has rocketed just shy of 30%. The shares have more than tripled in the past year.

That’s all due to favourable results coming from testing of its copper therapies on prostate cancer patients.

Back in January, Frazis Capital portfolio manager Michael Frazis was full of praise for the Sydney biotech.

“This is the most exciting company I’ve come across in Australia lately.”

Providing hope for a bleak situation

Even though prostate cancer is common, the fact remains treatments can be soul-destroying for patients.

“Treatment involves radical prostatectomy to remove ‘the true heart of the male’, hormone therapy, and traditional radiotherapy and chemotherapy,” said Frazis in a memo to clients.

“These come with a bleak list of side effects: incontinence, impotence, loss of interest in sex, and depression.”

Clarity is one of a bunch of companies seeking to improve this situation.

“The hope is that the next generation of radiopharmaceuticals will be able to differentiate between harmless and metastatic disease, limit unnecessary treatments, catch any recurrence, and ultimately cure prostate cancer without such bleak side effects.”

Admittedly the $717 million company is sparsely covered by professional investors at the moment.

But broking platform CMC Invest shows at least Jefferies and Wilsons rating Clarity Pharmaceuticals as a buy currently.

The post 1 ASX stock to consider buying that could be the next ResMed appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why this ASX biotech stock could rise a massive 40%
• GLP-1 obesity medicines do the opposite of what ResMed stock investors feared
• A once-in-a-decade chance to get rich buying ASX growth stocks?
• 2 ASX 200 shares to buy in the most ‘interesting’ sector right now
• Bell Potter names the best ASX shares to buy in March

Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/H41JFEb

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why is the ASX 200 retreating from this month’s all-time highs?
• 5 things to watch on the ASX 200 on Monday
• Top brokers name 3 ASX shares to buy next week
• Here’s how the ASX 200 market sectors stacked up last week
• These ASX shares could rise 20% to 50%

Motley Fool contributor Sebastian Bowen has positions in A2 Milk. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and Telix Pharmaceuticals. The Motley Fool Australia has recommended A2 Milk and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/UdvKEw4

If you’re on the lookout for big returns, then you may want to check out Clarity Pharmaceuticals Ltd (ASX: CU6).

That’s because analysts at Bell Potter believe that the ASX biotech stock could generate big returns for investors with a high tolerance for risk over the next 12 months.

What is the broker saying about this ASX biotech stock?

According to a note, the broker was pleased with its recent announcement relating to the SECuRE trial, which is investigating the therapeutic qualities of 67Cu-SAR-bisPSMA in metastatic castrate resistant prostate cancer (mCRPC).

That announcement revealed that the preliminary data showed that despite having high levels of prostate-specific antigen (PSA) and having received multiple treatments, 60% of participants across all cohorts showed reductions in PSA levels of greater than 35% from a single therapy cycle of 67Cu-SAR-bisPSMA.

In addition, no dose limiting toxicities (DLTs) have been reported in cohort 3 to date, with most adverse events being mild or moderate and comfortably below levels that would cause investigators genuine concern.

In response to the trial data, Bell Potter said:

All cohorts have shown encouraging levels of reduction in PSA from a single dose of therapy. The announcement does not include progression free survival data, however, case studies from the EAP group which have now received multiple doses are highly encouraging, both from a safety and efficacy standpoint. Each of these patients remains alive and apparently with no disease progression, many months after commencing treatment. In one case PSA has reduced to undetectable levels with PET imaging showing a near complete response.

In summary, very pleasing data from SECuRE, strongly supportive of further investigation.

Major upside ahead

Bell Potter has held firm with its speculative buy rating and $3.90 price target on the ASX biotech stock.

Based on its current share price of $2.75, this implies potential upside of 42% for investors over next 12 months.

Though, it is worth remembering that its rating comes with a speculative tag. This means it may only be suitable for investors with a high tolerance for risk.

The post Why this ASX biotech stock could rise a massive 40% appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 3 ASX 200 mining shares to buy now with less than $1,000
• Leading brokers name 3 ASX shares to buy today
• 2 ASX 200 shares to buy that are ‘catalyst rich’
• Why Bannerman Energy, Cettire, TechnologyOne, and Zip shares are charging higher
• Why Arafura Rare Earths, Core Lithium, Goodman, and Superloop shares are falling today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/vBbVqFx

Looking for ASX shares to buy now without spending a fortune?

Below we look at three top S&P/ASX 200 Index (ASX: XJO) mining stocks that have been heavily sold down in 2024.

While that doesn’t necessarily mean they might not have further to fall shorter-term, I believe these are ASX shares to buy now for patient investors with an eye on long-term gains. Not to mention the two fully franked dividend payments they’ll receive each year.

ASX mining shares to buy now with less than $1,000

You’re most likely familiar with the three ASX 200 mining stocks in question.

Namely Fortescue Metals Group Ltd (ASX: FMG), BHP Group Ltd (ASX: BHP) and Rio Tinto Ltd (ASX: RIO).

Here’s how they’ve performed so far in 2024:

• BHP shares are down 16% at $42.37
• Rio Tinto shares are down 14% at $117.34
• Fortescue shares are down 19% at $23.80

Now you’ll notice that Rio Tinto shares trade for almost five times as much as Fortescue shares and nearly three times as much as BHP shares. So, the amount of these ASX shares to buy now will depend on whether you want to own the same number of shares in each company or spread your $1,000 evenly between them.

Why have the ASX 200 miners come under selling pressure?

I believe after the big 2024 sell-off, these three ASX shares are good buys now.

Some of the selling pressure has come amid a rout in nickel markets, with Indonesia ramping up its nickel mining. That’s seen the Australian miners call for a global distinction between environmentally friendlier “clean nickel” and the much cheaper “dirty nickel” that comes from Indonesia.

While that process is still evolving, I believe a world focused on sustainability will eventually reward the big miners for their cleaner nickel by paying higher prices, or by taxing dirty nickel producers. Either way, investors buying these ASX shares now could see an uptick in their fortunes down the road.

The biggest headwind that’s hit these ASX 200 mining stocks in 2024, however, is the big fall in iron ore.

Iron ore counts as the biggest revenue earner for all three companies.

The steel-making metal kicked off 2024 trading for US$145 per tonne. But it’s been mostly downhill from there.

Iron ore dipped below US$100 per tonne on Friday amid ongoing concerns over rising Chinese stockpiles and lower levels of steel manufacturing.

As to where iron ore will be trading over the rest of the year and in 2025, forecasts vary from lows of US$85 per tonne to highs of more than $125 per tonne.

And a lot of that will depend on China’s growth outlook.

Capital Economics’ chief Asia economist Mark Williams, has this rather bearish take on China’s real estate sector (courtesy of The Australian Financial Review):

Property sales and project starts have collapsed. But property construction activity has retreated only a little. It is likely to halve in the next few years, triggering similar falls in demand for construction inputs.

So, why do I think these are still three ASX shares to buy now?

Largely, because I don’t believe Chinese President Xi Jinping can afford to let China’s economy slide much further. Meaning the rather tepid stimulus measures we’ve seen from the Chinese government over recent months could see some sizeable boosts yet this year.

I’m also encouraged by the fact that copper prices have gained more than 6% in 2024, trading for US$8,545 per tonne on Friday.

That bodes well for the prospects of broader global growth. This should support the medium-term outlook for the big miners and bolsters the case to buy these three ASX shares now after 2024’s big sell-down.

And don’t forget the dividends you’ll get from buying these ASX shares.

Despite their payouts falling from the 2022 highs, the retrace in the big miners’ share prices still sees them trading at some juicy, fully franked yields.

At current share prices:

• BHP shares trade on a yield of 5.5%
• Rio Tinto shares trade on a yield of 56%
• Fortescue shares trade on a yield of 8.8%

The post 3 ASX 200 mining shares to buy now with less than $1,000 appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Fortescue shares retreat to fresh 2024 low as iron ore breaks below US$100 per tonne
• Buy Woodside shares and these ASX 200 dividend giants now
• Where will Fortescue shares be in 3 years?
• If I invest $10,000 into BHP shares, how much passive income will I receive?
• Brokers name 3 ASX shares to buy now

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/KMFr01A

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

Boss Energy Ltd (ASX: BOE)

According to a note out of Macquarie, its analysts have retained their outperform rating and $6.00 price target on this uranium miner’s shares. Macquarie was pleased with the company’s performance during the first half, noting that its underlying result was in line with expectations and its reported result smashed estimates. The broker is feeling positive about the future thanks to the restart of the Honeymoon project and its organic growth optionality. In addition, it highlights that spot prices are currently trading well above its forecasts. This could be good news for its earnings and valuation if they remain at these levels for longer. The Boss Energy share price is trading at $4.83 today.

Hub24 Ltd (ASX: HUB)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $44.00 price target on this investment platform provider’s shares. Morgan Stanley has picked out the company as a standout from last month’s earnings season. It has been impressed with the way HUB24 has disrupted the platform market and believes there’s more to come in the future. Particularly given its expectation that the structural tailwinds it has been experiencing will continue. The broker also points out that it trades at a discount to its ASX listed rival despite stronger platform inflows. The HUB24 share price is fetching $40.36 on Monday.

Perpetual Ltd (ASX: PPT)

Analysts at Bell Potter have retained their buy rating on this fund manager’s shares with a trimmed price target of $27.15. The broker is feeling positive about Perpetual’s strategic review and believes it could be used to either close the valuation discount or become an acquisition target. The latter is based on the company owning attractive and valuable assets (particularly Corporate Trust and Wealth Management in the current environment). Overall, the broker feels that the market is not seeing the full value of the company, noting that it trades at a wide discount to a sum-of-the-parts valuation. The Perpetual share price is trading at $24.43 this afternoon.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Monday
• 6 ASX 200 shares with ex-dividend dates next week
• Why Core Lithium, Jupiter Mines, Newmont, and Perpetual shares are dropping today
• What’s happening with ASX uranium shares today?
• 13 ASX 200 shares with ex-dividend dates next week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/W9ZAbxX

The fund manager Wilson Asset Management (WAM) has revealed two S&P/ASX 200 Index (ASX: XJO) shares where there are multiple reasons to think they can deliver good performance.

WAM Leaders Ltd (ASX: WLE) is a listed investment company (LIC) that largely focuses on businesses with larger market capitalisations. Below are two stocks that the investment team likes within the portfolio.

WiseTech Global Ltd (ASX: WTC)

It was recently the ASX reporting season and WAM enjoyed the “strong result” from WiseTech. The investment team said the ASX tech share demonstrated “its ability to integrate its recently-acquired businesses called Blume and Envase, without losing the organic growth momentum.”

The fund manager also said the ASX 200 share remained diligent on costs and positively surprised the market with its profit margin outlook.  

Another positive from the report update was the announcement of three major new customer wins in the Asian region during the period, including Sinotrans, a large Chinese shipping company. This win meant WiseTech now has 13 of the top 25 global freight forwarders.

WAM Leaders said the report and customer wins validated the value proposition of WiseTech’s core software platform (CargoWise) and its continued traction in the core global freight forwarding market. The investment team concluded:

We remain positive on WiseTech as we see the company continuing to gain market share in a large industry, led by its technology platform and new product launches as the company continues to invest in its product and technology for future growth.

Santos Ltd (ASX: STO)

Santos also recently reported its result to the market, though this one was “slightly below” market expectations.

The ASX 200 share didn’t meet investors’ forecasts because of “other” costs, including inventory and foreign exchange movements.

However, WAM Leaders pointed out the ASX oil and gas share reconfirmed its full-year guidance and declared an “outsized” dividend that was reportedly ahead of expectations.

Santos said it’s committed to reducing the gap between the Santos share price and the value of its underlying asset base while returning additional cash flow to shareholders.

The investment team said:            

We remain constructive on Santos as we see the company being catalyst rich, including potential strategic structural changes, as well as successful project executions in Barrosa and Alaska, which will de-lever the balance sheet and further improve cash flow performance.

The post 2 ASX 200 shares to buy that are ‘catalyst rich’ appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Monday
• 5 things to watch on the ASX 200 on Tuesday
• Why Santos shares may be ‘one of the most attractive globally’
• 5 things to watch on the ASX 200 on Monday
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/IujhMJO